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The aim of this study was to evaluate the GenoFlow DR-MTB array test (DiagCor Bioscience, Hong Kong) on 70 cultured isolates
and 50 sputum specimens. The GenoFlow array test showed good sensitivity and specificity compared to the phenotypic Bactec
460TB. This array accurately detected mutations in rpoB, katG, and inhA associated with resistance to rifampin and isoniazid.
Rapid detection and drug susceptibility testing of Mycobacte-rium tuberculosis are hampered by the slow growth of myco-
bacteria (1). The transmission of strains resistant to both rifampin
(RIF) and isoniazid (INH), i.e., multidrug-resistant (MDR)
strains, remains a public health problem. These strains may har-
bor mutations in rpoB (2, 3), katG, and inhA, among other
genomic regions (4, 5). The aim of this study was to evaluate the
diagnostic accuracy of the GenoFlow DR-MTB array test (Diag-
Cor Bioscience, Hong Kong) for the detection of M. tuberculosis
molecular resistance to RIF and INH.
A total of 70 M. tuberculosis isolates from 70 patients and 50
sputum specimens from 25 patients (more than one specimen was
obtained from nine patients) were retrospectively selected from a
collection of cultured isolates and specimens recovered from the
Hospital Universitari Germans Trias i Pujol (Badalona, Spain),
the Instituto Aragonés de Ciencias de la Salud (Zaragoza, Spain),
and Serveis Clínics (Barcelona, Spain). The isolates and specimens
were selected to represent different resistance profiles. The study
was approved by the institutional ethics committee at Hospital
Universitari Germans Trias i Pujol.
Specimens were decontaminated using Kubica’s N-acetyl-L-
cysteine NaOH method (6, 7), stained by auramine-rhodamine,
graded on a scale from 0 to 3, and cultured on Lowenstein-
Jensen and Bactec 460TB (Becton Dickinson, Sparks, MD, USA).
The remaining decontaminated specimens were stored at20°C
(8). The INNO-LiPA mycobacteria version 2 assay (Innogenetics,
Ghent, Belgium) was used to identify M. tuberculosis complex or-
ganisms for all the isolates and cultures from the specimens. Drug
susceptibility testing (DST) was performed with Bactec 460TB
(Bactec) using 2g/ml RIF and 0.1g/ml INH as critical concen-
trations (9).
For molecular drug resistance detection, DNA from isolates
and specimens was extracted, as previously described (10). The
GenoFlow array test consists of PCR amplification and hybridiza-
tion in the FTPRO flowthrough system. The mutations targeted are
rpoB D516V, D516G, H526D, H526Y, H526L1, S531L, and
S531W; katG S315T1 and S315T2; and inhA C-15T. An internal
amplification control, hybridization control, and rpoB, katG, and
inhA controls were included in each reaction. The results obtained
by the array were recorded, automatically interpreted by the Diag-
Cor software, and confirmed visually by the researcher. These
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TABLE 1 Distribution of GenoFlow DR-MTB array results according to Bactec 460TB for 70 clinical isolates and 50 sputum specimens
GenoFlow resulta
Bactec 460TB result (%) for (n)b:
Clinical isolates (70) Sputum specimens (50)
RIF INH MDR (23) RIF INH MDR (37)
R (23) S (47) R (59) S (11) RIF INH R (37) S (13) R (40) S (10) RIF INH
R 22 41 22 17 35 1 38 35 36
S 1 47 18 11 1 6 2 11 1 10 2 1
I 1c 1c
a R, resistant; S, sensitive; I, invalid.
b RIF, rifampin; INH, isoniazid; MDR, multidrug resistant (resistant to both rifampin and isoniazid).
c Invalid GenoFlow results for both RIF and INH were obtained for the same specimen.
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results were compared to those obtained by the Bactec. Discordant
results between the array and the Bactec were compared to those
obtained by alternative molecular methods. DNA sequencing tar-
geted mutations in the katG gene, oxyR-ahpC, mabA-inhA, and
the 81-bp core region of rpoB (11); the GenoType MTBDRplus
(Hain Lifescience, Nehren, Germany) targeted mutations in rpoB
(codons 516, 526, and 531), katG (codon 315), and inhA (posi-
tions8,15, and16) (10); and pyrosequencing targeted mu-
tations in rpoB (codons 516 and 526 to 531), katG (codon 315),
and inhA (positions 16 to 5) (12). This diagnostic accuracy
study was reported in accordance with the Standards for Report-
ing of Diagnostic Accuracy (STARD) statement guidelines (13).
The distribution of GenoFlow results, according to the Bactec
results for clinical isolates and sputum specimens, is presented in
Table 1. The sensitivity, specificity, and agreement between the
GenoFlow and Bactec tests were 90% for detecting RIF resis-
tance in cultured isolates and sputum specimens and for INH
resistance in sputum specimens; however, the sensitivity of the
array for INH resistance in clinical isolates was 69.5% (Table 2). A
total of 23 discordant results were obtained between Bactec and
GenoFlow tests for 22 isolates/specimens (for one isolate, discrep-
ant results were obtained for both drugs) (Table 3). At least one of
the results obtained by DNA sequencing, GenoType MTBDRplus,
or pyrosequencing was in agreement with the array in 82.6% (19/
23) of the cases.
Of the 50 sputum specimens selected, two were smear negative,
and 48 were smear positive; eight specimens were smear 1 (1 to
10 acid-fast bacilli [AFB] per 100 fields), nine specimens were
smear 2 (1 to 9 AFB per field), and 31 specimens were smear 3
(9 AFB per field). An invalid GenoFlow test result (absence of
katG and inhA controls) was obtained for one specimen, which
was 3 and rifampin sensitive/isoniazid resistant. For four spec-
imens, discordant results between the Bactec and GenoFlow tests
were obtained: one specimen was smear negative, one specimen
was smear 1, and two specimens were smear 3 (Table 3). Fur-
thermore, for two of the specimens with a discordant result be-
tween the Bactec and GenoFlow tests, consecutive samples col-
lected during the treatment were available, and a concordant
result was obtained for those specimens. Thus, the molecular re-
sult did not appear to be affected by potential changes in the DST
profile or in the different resistant/susceptible subpopulations in
the sample during the treatment of the patients.
The sensitivity and specificity values of the GenoFlow test for
detecting RIF resistance were comparable to those of GenoType
MTBDRplus and INNO-LiPA Rif. TB assays (14). These high val-
ues were expected, since95% of rifampin-resistant isolates har-
bor mutations in the targeted region of rpoB (15). Regarding INH
resistance, the lower sensitivity of the GenoFlow test was partially
in contrast with that of the GenoType MTBDRplus assay (16). The
data presented here, despite the bias introduced in the selection of
isolates, was more in accordance with those of another systematic
review that reported a combined cumulative frequency of 79.9%
for katG codon 315 and inhA position15 mutations worldwide,
which reached 83.9% when additional mutations in inhA and
ahpC were included (17).
Nowadays, several molecular tests are available (18–21), but
more studies are still needed to assess their clinical value. For
instance, an evaluation has demonstrated the noninferiority of the
GenoType MTBDRplus version 2.0 and Nipro line probe assays in
comparison to the WHO-endorsed first version of the GenoType
T
A
B
LE
2
Sen
sitivity
an
d
specifi
city
ofG
en
oFlow
D
R
-M
T
B
array
for
detectin
g
dru
g
resistan
ce,an
d
agreem
en
t
valu
es
betw
een
G
en
oFlow
D
R
-M
T
B
array
an
d
B
actec
460T
B
a
R
esistan
ce
C
lin
icalisolates
Spu
tu
m
specim
en
s
Sen
sitivity
(n
o.
detected/totaln
o.[%
]
[95%
C
I])
Specifi
city
(n
o.
detected/totaln
o.[%
]
[95%
C
I])
b
A
greem
en
t
(n
o.detected/
totaln
o.[%
])
K
appa
c
SE
Sen
sitivity
(n
o.
detected/totaln
o.[%
]
[95%
C
I])
Specifi
city
(n
o.
detected/totaln
o.[%
]
[95%
C
I])
b
A
greem
en
t
(n
o.detected/
totaln
o.[%
])
K
appa
c
SE
R
IF
22/23
(95.7)
(76.0–99.8)
47/47
(100)
(90.6–100)
69/70
(98.6)
0.967
0.032
35/37
(94.6)
(80.5–99.1)
11/12
(91.7)
(59.8–99.6)
46/49
(93.9)
0.839
0.090
IN
H
41/59
(69.5)
(56.0–80.5)
11/11
(100)
(67.9–100)
52/70
(74.3)
0.417
0.096
38/39
(97.4)
(84.9–99.9)
10/10
(100)
(65.5–100)
48/49
(98.0)
0.939
0.060
M
D
R
17/23
(73.9)
(51.3–88.9)
47/47
(100)
(90.6–100)
b
64/70
(91.4)
0.792
0.079
34/37
(91.9)
(77.0–97.9)
13/13
(100)
(71.7–100)
b
47/50
(94.0)
0.847
0.084
a
R
IF,rifam
pin
;IN
H
,ison
iazid;M
D
R
,m
u
ltidru
g
resistan
ce
(resistan
ce
to
both
rifam
pin
an
d
ison
iazid);C
I,con
fi
den
ce
in
terval;SE
,stan
dard
error.
b
For
specifi
city
calcu
lation
s
ofM
D
R
detection
,w
e
con
sidered
isolates/specim
en
s
sen
sitive
to
eith
er
R
IF
or
IN
H
or
both
.
cK
appa
valu
es
of
0.6
an
d
kappa
valu
es
betw
een
0.4
an
d
0.6
in
dicate
a
stron
g
an
d
m
oderate
agreem
en
t,respectively.
TB RIF and INH Resistance Detection
April 2016 Volume 54 Number 4 jcm.asm.org 1161Journal of Clinical Microbiology
 o
n
 M
arch 23, 2017 by UNIVERSIDAD DE ZARAG
O
ZA
http://jcm.asm.org/
D
ow
nloaded from
 
MTBDRplus assay for the rapid detection of multidrug-resistant
tuberculosis (MDR-TB) (22). Moreover, in order to improve pa-
tient management, it is important to consider not only the molec-
ular result (presence/absence of mutation) but also the mutation
detected and its correlation with the phenotypic result and clinical
outcome (23).
The main advantages of the GenoFlow assay were the use of the
FTPRO hybridization device, which shortens the hybridization
protocol to 45 min (that of the GenoType MTBDRplus assay is 2
h), and the specific software that facilitates the interpretation, re-
port, and storage of the results. In addition, an automated hybrid-
ization device is under development, which may reduce the
hands-on-time of the hybridization step. Another aspect that
could also be improved is the low-throughput capacity.
In conclusion, the GenoFlow assay may be useful for rapid,
sensitive, and specific screening of resistance to RIF and INH in
isolates and specimens, and its performance is comparable to that
of other molecular methods. Although molecular results should
be confirmed by phenotypic testing, the identification of resis-
tance can be helpful to rule out drugs and improve the manage-
ment of tuberculosis patients.
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